All News / Firm News
Capital Royalty Establishes Strategic Advisory Committee
Capital Royalty L.P. announced today that it has established a Strategic Advisory Committee (“SAC”) comprised of world-class leaders with extensive experience in building global biopharmaceutical companies, managing large scale research and development initiatives, and developing national healthcare policies. Capital Royalty’s SAC was created to support the firm’s investment team in identifying emerging industry trends, broadening industry relationships around the globe, and evaluating new investment opportunities. Sidney Taurel, a Senior Advisor at Capital Royalty, is Chairman of the SAC and responsible for leading and directing the activities of the SAC. Mr. Taurel is joined on the SAC by Dr. Mark McClellan, Henri Termeer, and Dr. Tadataka “Tachi” Yamada.
Posted in Firm News on 11/16/2010
Capital Royalty Promotes Mike Weinmann to Managing Director
“Mike has been an invaluable asset to Capital Royalty since joining the Firm as a Principal in March of 2009. Mr. Weinmann’s commanding knowledge of the royalty space, intimate involvement in the creation of the royalty bond product, and extensive industry relationships have been integral to Capital Royalty’s success and investment performance over the past year. This promotion reflects his past achievements as well as our expectations for his continued leadership as a senior member of the management team,” said Charles Tate, Founding Partner and Chairman.
Posted in Firm News on 05/20/2010
Capital Royalty Strengthens Royalty Investment Team With Three New Appointments
Capital Royalty L.P. announced today that it continues to expand and strengthen its royalty investment team with three new appointments – Andrei Dorenbaum as General Counsel and Executive Director, Peter Faroni as Associate, and James Tate as Analyst. Mr. Dorenbaum will operate out of the Firm’s Houston headquarters, while Messrs. Faroni and Tate will join Michael Weinmann in the Firm’s New York office.
Posted in Firm News on 03/22/2010
Pharmaceutical Industry Veteran and Pioneer Sidney Taurel Joins Capital Royalty as Senior Advisor
Mr. Taurel brings a lifetime career of pharmaceutical industry experience and leadership, including 37 years at Eli Lilly and Co. where he served successively as President of Lilly International, President and Chief Operating Officer of the Company, and a decade as Chief Executive Officer and Chairman. A visionary and pioneer in transforming his own industry, Mr. Taurel was integral in shaping Lilly’s long-term future direction, including a strategic focus in building product pipelines through partnerships and licensing activities, many of which created large royalty streams. Over his career, Mr. Taurel completed over $30 billion in acquisitions and licensing transactions.
Posted in Firm News on 03/01/2010
Capital Royalty Enhances Royalty Investment Team With New Principals Weinmann and Düster
“Our stated goal is to strengthen and position Capital Royalty for market leadership in healthcare investing for the future. Our plan is three-fold: assemble a world-class investment team that unites the finest pioneers and innovators in healthcare financing; sharpen our collective vision to enhance our competitive market advantage; and, refine our royalty investment strategy to attract the highest-quality IP assets through the design of innovative royalty financing structures,” said Charles W. Tate, Capital Royalty Founder and Chairman.
Posted in Firm News on 03/06/2009
Nathan Hukill Joins Capital Royalty as Managing Director
Mr. Hukill brings over a decade of investing and structuring experience to Capital Royalty, most recently as a Portfolio Manager at Highland Capital Management, L.P, a registered investment advisor with over $20 billion of assets under management, where he invested and managed approximately $4.5 billion in alternative assets focused primarily on healthcare investments. Mr. Hukill spearheaded Highland Capital’s entry into biopharmaceutical royalties, becoming the largest buyer of biopharmaceutical royalty bonds in the industry.
Posted in Firm News on 01/21/2009